Sanofi Genzyme retreats from its Parkinson’s deal with gene therapy upstart Voyager, part of an $845M pact
Voyager $VYGR plans to launch a pivotal study of its leading gene therapy for Parkinson’s disease before the end of the year, but they won …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
